Rising KashmirRising KashmirRising Kashmir
  • Home
  • Top Stories
  • News
    • Kashmir
    • City
    • Jammu
    • Politics
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Search

Archives

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022

Categories

  • Anchor
  • Breaking
  • Business
  • City
  • Developing Story
  • Editorial
  • Education
  • Features
  • Health
  • Interview
  • Jammu
  • Jammu and Kashmir News
  • Kashmir
  • Kashmir Tourism
  • Kath Bath
  • National
  • Opinion
  • Politics
  • Sports
  • Technology
  • Top Stories
  • Trending
  • Uncategorized
  • Video
  • Viewpoint
  • World
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Reading: New medicine discovered to be beneficial for treating complicated urinary tract infections
Share
Notification Show More
Font ResizerAa
Rising KashmirRising Kashmir
Font ResizerAa
  • Home
  • Top Stories
  • News
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Search
  • Home
  • Top Stories
  • News
    • Kashmir
    • City
    • Jammu
    • Politics
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Follow US
© 2024. All Rights Reserved.
Rising Kashmir > Blog > Breaking > New medicine discovered to be beneficial for treating complicated urinary tract infections
Breaking

New medicine discovered to be beneficial for treating complicated urinary tract infections

ANI
Last updated: October 30, 2022 3:22 pm
ANI
Published: October 30, 2022
Share
4 Min Read
SHARE

According to an international study conducted by a Rutgers expert comparing new and older medicines for complicated urinary tract infections, a new medicine combination has been found to be more effective, particularly against chronic, drug-resistant infections.

Describing the results in the Journal of the American Medical Association (JAMA), researchers in the ALLIUM Phase 3 clinical trial showed that a combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation, than a standard treatment combining piperacillin and tazobactam. Urinary tract infections are considered complicated when they are associated with risk factors – including fevers, sepsis, urinary obstruction or catheters – that increase the danger of failing antibiotic therapy. “This new antibiotic was superior to the standard-of-care therapy,” said Keith Kaye, chief of the Division of Allergy, Immunology and Infectious Diseases and a professor of medicine at Rutgers Robert Wood Johnson Medical School.

“It represents an exciting option for treatment,” said Kaye, the principal investigator of the study and lead author on the publication.

Kaye added this drug combination also fights an often-dangerous category of bacterial illnesses caused by pathogens known as extended spectrum beta-lactamase (ESBL) infections, named for an enzyme the bacteria produce. ESBL-producing bacteria can’t be killed effectively by many of the antibiotics conventionally used to treat infections, such as penicillins and cephalosporins.

“We are looking for antibiotics that are active against resistant bacteria, such as ESBLs, and we found this new combination to be highly effective,” Kaye said.

The trial was conducted at 90 sites in Europe, North and Central America, South America and South Africa from September 2018 to November 2019. More than 1,000 patients participated in the study. Some 79 percent of the patients receiving the new combination of cefepime and enmetazobactam were successfully treated for their illness, as opposed to 58.9 percent of those receiving the conventional treatment of piperacillin and tazobactam.

Of the 20 percent of patients from the overall group belonging to the subset of those with ESBL infections, 73 percent of the patients receiving cefepime and enmetazobactam achieved a clinical cure, as opposed to 51 percent of the patients on the standard therapy.

The antibiotic cefepime is a fourth-generation cephalosporin that was approved for use in the 1990s and is available generically. Enmetazobactam, an experimental drug made by the French biopharmaceutical company Allecra Therapeutics, is a beta-lactamase inhibitor, meaning it attacks the beta-lactamases, including the types of enzymes produced by ESBL-producing bacteria. The drug combination has been granted Qualified Infectious Disease Product and Fast Track designation by the U.S. Food and Drug Administration (FDA).

Kaye said he expected the company to apply for FDA approval early next year.

More than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die from them, according to a report from the U.S. Centers for Disease Control and Prevention (CDC). In a 2019 study on antibiotic resistance, the CDC characterized ESBLs as a serious threat to human health. (ANI)

Senior advocate Ashok Bhan greets people on Navreh and Eid-ul-Fitr
India, UAE to collaborate in fields of industries, advanced technologies; MoU inked
PM Modi welcomes Italian PM Giorgia Meloni to India
CS kick starts ‘JJM Fortnight’ for certification of ‘Har Ghar Nal Se Jal’
Man killed in Anantnag road accident

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
Previous Article Huge Public Participation witnessed in B2V4 at Shadab Karewa Shopian
Next Article PM Modi’s ‘Sab Ka Sath, Sab Ka Vikas, Sab Ka Vishwas’ made J&K “hub of tourism”: Tarun Chug
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

1MFollowersLike
262kFollowersFollow
InstagramFollow
234kSubscribersSubscribe
Google NewsFollow

Latest News

India’s Purple Revolution to take centre stage at Bhaderwah festival
Jammu
May 30, 2025
Minister Javaid Dar launches ‘Viksit Krishi Sankalp Abhiyan’ at SKUAST-K
Kashmir
May 30, 2025
SMC Comm reviews preparations for Mela Kheer Bhawani, Eid-ul-Adha
Kashmir
May 30, 2025
Tourism revival in J&K: Bollywood actress Huma Qureshi interacts with CTTIK delegation, vows support
Jammu
May 30, 2025

Recent Posts

  • India’s Purple Revolution to take centre stage at Bhaderwah festival
  • Minister Javaid Dar launches ‘Viksit Krishi Sankalp Abhiyan’ at SKUAST-K
  • SMC Comm reviews preparations for Mela Kheer Bhawani, Eid-ul-Adha
  • Tourism revival in J&K: Bollywood actress Huma Qureshi interacts with CTTIK delegation, vows support
  • Civil Defence organises awareness camp at GCW Gandhi Nagar

Recent Comments

  1. BASHIR AHMAD BHAT on Poor hotel accommodation, lack of medical facilities irk Kashmiri pilgrims in Saudi Arabia, video goes viral
  2. sree vishnu movies on Pahalgam attack shatters Kashmir’s film tourism revival
  3. SavePlus on AI and Behavioural Analytics in Gaming: Making the World of Gaming Better
  4. Parul on Govt acknowledges faulty streetlights on Narbal-Tangmarg road
  5. dr gora on Women Veterinarians and the Goal of Viksit Bharat

Contact Us

Flat No 7,Press Enclave, Srinagar, 190001
0194 2477887
9971795706
[email protected]
[email protected]

Quick Link

  • E-Paper
  • About Us
  • Contact Us

Top Categories

Stay Connected

1.06MLike
262.5kFollow
InstagramFollow
234.3kSubscribe
WhatsAppFollow
Rising KashmirRising Kashmir
Follow US
© 2025. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?